Vaccines Go Global: Life-Sciences Translation Demand Keeps Heating Up

In 2021, the global race to develop and administer vaccines unfolded at full speed, and translation demand in the life sciences heated up accordingly. From clinical trial protocols and informed consent forms to drug registration dossiers, GMP documentation and public vaccination guidance, every link requires rigorous multilingual support.

What makes pharmaceutical translation special is zero tolerance for error: dosages, contraindications and adverse-reaction statements admit no ambiguity — a mistranslated number or negation can have serious consequences. Life-sciences translation has therefore long been led by professional linguists with medical or pharmaceutical backgrounds, backed by strict review and terminology management.

The internationalization of Chinese vaccine and pharmaceutical companies is adding volume in pairs such as Chinese-English, Chinese-Spanish and Chinese-Arabic. Overseas clinical trials and regulatory submissions for Chinese-developed vaccines require large volumes of dossier translation meeting target-country regulators' requirements; and as traditional Chinese medicine goes global, standardized terminology translation is a long-term project of its own.

The industry expects that even after the pandemic recedes, international collaboration in pharmaceutical R&D will not reverse. The professional barriers of life-sciences translation make it one of the most cycle-resistant segments of the translation market.